Photodynamic therapy for inflammatory CNV: Do we know enough?

Ocular Immunology and Inflammation

Volumn 13, Issue 5, 2005, Pages 331-333

  Kramer, Michal ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EDITORIAL; FOLLOW UP; HUMAN; OCULAR HISTOPLASMOSIS; PHOTODYNAMIC THERAPY; PROBABILITY; RETINITIS; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISUAL ACUITY;

CHOROIDAL NEOVASCULARIZATION; HUMANS; MACULAR DEGENERATION; MYOPIA; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; TREATMENT OUTCOME;

EID: 28244433818     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.1080/09273940500351067     Document Type: Editorial

References (19)

1. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of sub-foveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials - TAP Report 2. Arch Ophthalmol. 2001;119:198-207.
2. Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfovel choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-Verteporfin In Photodynamic Therapy Report 2. Am J Ophthalmol. 2001;131:541-560.
3. Verteporfin In Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial - VIP Report No. 3. Ophthalmology. 2003;110:667-673.
4. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) and Verteporfin In Photodynamic Therapy (VIP) Study Groups. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration - TAP and VIP Report No. 1. Am J Ophthalmol. 2003;136:407-418.
5. Rogers AH, Duker SJ, Nichols N, Baker BJ. Photodynamic therapy of idiopathic and inflammatory choroidal neovascularization in young adults. Ophthalmology. 2003;110:1315-1320.
6. Wachtlin J, Heimann H, Behme T, Foerster MH. Long-term results after photodynamic therapy with verteporfin for choroidal neovascularizations secondary to inflammatory chorioretinal diseases. Graefe's Arch Clin Exp Ophthalmol, 2003;241:899-906.
7. Leslie T, Lois N, Christopoulou D, Olson JA, Forrester JV. Photodynamic therapy for inflammatory choroidal neovascularization unresponsive to immunosuppression. Br J Ophthalmol. 2005;89:147-150.
8. Dunlop AAS, Cree IA, Hague S, Luthert PJ, Lightman S. Multifocal Choroiditis: Clinicopathologic Correlation. Arch Ophthalmol. 1998; 116:801-803.
9. Flaxel CJ, Owens SL, Mulholland B, Schwartz SD, Gregor ZJ. The use of corticosteriods for choroidal neovascularization in young patients. Eye. 1998;12:266-272.
10. Dees C, Arnold JJ, Forrester JV, Dick AD. Immunosuppressive treatment of choroidal neovascularization associated with endogenous posterior uveitis. Arch Ophthalmol. 1998;116:1456-1461.
11. Rogers AH, Martidis A, Greenberg PB, Puliafito CA. Optical Coherence Tomography findings following photodynamic therapy of choroidal neovascularization. Am J Ophthalmol. 2002;134:566-576.
12. Treatment of Age-related Macular Degeneration With Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP Report 1. Arch Ophthalmol. 1999;117:1329-1345.
13. Schlingemann RO. Role of growth factors and the wound healing response in age-related macular degeneration. Graefe's Arch Clin Exp Ophthalmol. 2004;242:91-101.
14. Grossniklaus HE, Ling JX, Wallace TM, et al. Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Molecular Vision. 2002;8:119-26.
15. Reddy VM, Zamora RL, Kaplan HJ. Distribution of growth factors in subfoveal neovascular membranes in age-related macular degeneration and presumed ocular histoplasmosis syndrome. Am J Ophthalmol. 1995;120:291-301.
16. Ciulla TA, Walker JD, Fong DS, Criswell MH. Corticosteroids in posterior segment disease: an update on new delivery systems and new indications. Curr Opin Ophthalmol. 2004;15:211-220.
17. Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology. 2005;112:301-4.
18. Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805-2816.
19. Michels S, Rosenfeld PJ. Treatment of neovascular age-related macular degeneration with Rantizunab/Lucentis. Klin Monatsbl Augenheilkd. 2005;222:480-484.